Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed

This study has been completed.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: November 17, 2004
Last updated: March 12, 2014
Last verified: March 2014